A procedurally activatable nanoplatform for chemo/chemodynamic synergistic therapy.

Area of Science:

• Biomedical Engineering
• Materials Science
• Nanotechnology

Background:

• Tumor microenvironment (TME) characteristics like pH, hypoxia, and H2O2 offer opportunities for targeted drug delivery.
• Multi-responsive nano-drug delivery systems can improve drug efficacy and reduce side effects.

Purpose of the Study:

• To develop a H2O2/GSH procedurally activatable nanoplatform (Cu9S5-PEG/DOX NSs) for tumor-specific synergistic therapy.
• To investigate the sequential activation mechanism and therapeutic potential of the nanoplatform.

Main Methods:

• Fabrication of Cu9S5-PEG/DOX NSs for responsive drug release and co-activated Fenton agent.
• In vitro evaluation of nanoplatform response to H2O2 and GSH within tumor cells.
• Assessment of doxorubicin (DOX) release, copper ion liberation, and hydroxyl radical generation.

Main Results:

• Cu9S5-PEG/DOX NSs transformed from nanosheets to nanoflowers upon H2O2 exposure, releasing DOX.
• Subsequent reaction with GSH liberated copper ions and induced GSH depletion.
• The system demonstrated sequential activation, enhanced DOX release, and generation of toxic hydroxyl radicals via a copper-based Fenton-like reaction.
• The nanoplatform exhibited high cytotoxicity to tumor cells while sparing normal cells.

Conclusions:

• The Cu9S5-PEG/DOX NSs function as a procedurally activatable nanoplatform for tumor-specific synergistic therapy.
• This system holds significant potential for enhancing cancer treatment outcomes by leveraging TME-specific triggers.